MIP Discovery secures significant funding
Funding secured from Bill and Melinda Gates Foundation to expand disease testing.
Funding secured from Bill and Melinda Gates Foundation to expand disease testing.
Arctic Shores is leading the way to help employers build the diverse, successful workforce of tomorrow.
FTSE 250 company Hikma have triggered the transfer of Arecors’s AT307 product including a milestone payment.
Calculus CEO, John Glencross, gives an update on the happenings in Q4 2022.
Home Team will develop and produce premium television projects with UIS for the UK and global market
C4X Discovery continues its progress with the signing of an exclusive global license with AstraZeneca.
Calculus completes exit from Avvio for 5.5x return, a continuation of excellent exits achieved for Calculus investors in the last two years.
The Government is committed to helping entrepreneurial businesses raise growth capital by continued support of EIS and VCT
Destiny Pharma’s potentially revolutionary product ‘XF-73’ progresses into next stage study.
80% of OEM’s customers won’t have to rely on taxpayer support this winter Saving taxpayers over £250m versus full energy price cap payouts Keeping hundreds of businesses afloat and in control of their costs Open Energy Market (OEM), a leading provider of energy procurement services and net zero technologies, today quantifies the taxpayer savings made … Continued
Calculus sponsored the HNW wealth manager of the year award.
Arecor continue to make significant strides proving the strength of their technology.
Scancell continue progress for Modi-2 by in-licencing Vaccitech technology.
Arecor’s subsidiary launch a new treatment option for severe hypoglycaemia for children and adults living with diabetes.
Elizabeth Klein joins Calculus as a Director within the investment team, bringing a wealth of experience.
Scancell said it has enrolled its first patient in the expansion phase of its ModiFY trial.
Important note: Past performance is not indicative of future performance. Tax benefits depend on the individual circumstances of each investor and may be subject to change in the future. Welcome to our third quarterly update of 2022. This quarter, we are delighted to announce the launch of our HMRC approved Knowledge Intensive EIS Fund, whereby … Continued
Riff Raff Entertainment update on latest project and Brouhaha release first look of ‘Lee’.
Scancell Holdings, Calculus portfolio company, said it has signed a deal worth up to US$208m.
As UK Inflation hits 10.1% John Glencross, CEO of Calculus, Shares his views on the implications.
Wazoku becomes one of the world’s first innovation companies to achieve prestigious B-Corp recognition.
Calculus launches new Knowledge Intensive EIS fund, an HMRC approved Fund.
Oxford BioTherapeutics announce agreement with Genmab to add further depth and momentum into its drug pipeline.
Calculus has launched its new VCT share offer providing investors with access to the innovators and gamechangers who can grow and scale the UK’s businesses of the future.